Novartis

GSK to establish global vaccines R&D center in the U.S.

Monday, April 6, 2015 11:57 AM

GlaxoSmithKline is establishing a new global center for vaccines R&D in Rockville, Md. The site will become one of three global vaccines R&D centers for GSK, complementing the company’s existing global R&D center in Rixensart, Belgium and in Siena, Italy, a site GSK acquired from Novartis last month.

More... »

Quest Diagnostics

Aduro Biotech, Novartis collaborate on immuno-oncology products

Wednesday, April 1, 2015 12:50 PM

Aduro Biotech, a private, clinical-stage immuno-oncology company based in Berkeley, Calif., is collaborating with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro’s cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor, that, when activated, is known to initiate broad innate and adaptive tumor-specific immune responses.

More... »


FDA approves first biosimilar Zarxio from Sandoz

Friday, March 6, 2015 12:24 PM

Sandoz, a Novartis company, has became the first company to receive approval of a biosimilar in the U.S. through the new FDA biosimilar pathway established under the Biologics Price Competition and Innovation Act.

More... »

Array BioPharma purchases phase III assets from Novartis

Wednesday, March 4, 2015 01:07 PM

Array BioPharma has completed both the binimetinib and encorafenib definitive agreements with Novartis. Along with global ownership of both assets, Array will receive an upfront payment of $85 million from Novartis.

More... »

GSK, Novartis complete major three-part transaction

Monday, March 2, 2015 03:03 PM

GlaxoSmithKline and Novartis have completed their three-part transaction. As a result, GSK has acquired Novartis' global vaccines business (excluding influenza vaccines) for $5.25 billion and has divested its oncology business to Novartis for $16 billion. In addition, the two have created a new consumer healthcare joint venture in which GSK will have majority control and an equity interest of 63.5%.

More... »

Adimab, Sanofi collaborate on bispecific antibodies

Monday, February 9, 2015 12:20 PM

Adimab, a Lebanon, N.H.-based technology company focused on the discovery of fully human antibodies and bispecifics, has announced a multi-target discovery and optimization collaboration with Sanofi. Adimab will use its proprietary platform to generate bispecific molecules against multiple targets. Sanofi will have the right to develop and commercialize all therapeutic antibodies and bispecifics resulting from the collaboration.

More... »

Regulatory update on GSK-Novartis three-part transaction

Thursday, January 29, 2015 12:25 PM

GlaxoSmithKline has received clearance from the European Commission (E.C.) of its proposed three-part transaction with Novartis, which includes the acquisition of Novartis’s vaccines business (excluding influenza vaccines), the creation of a consumer healthcare joint venture between GSK and Novartis and the divestment to Novartis of GSK’s marketed oncology portfolio, related R&D activities and rights to two pipeline AKT inhibitors.

More... »

Array to acquire Novartis BRAF inhibitor encorafenib (LGX818)

Friday, January 23, 2015 11:40 AM

Array BioPharma, based in Boulder, Colo., has reached a definitive agreement with Novartis Pharma to acquire worldwide rights to encorafenib (LGX818), a BRAF inhibitor currently in phase III development. This agreement is conditional on the closing of transactions announced by Novartis and GlaxoSmithKline on April 22, 2014, which are expected to close in the first half of 2015, and the agreement remains subject to the receipt of regulatory approvals.

More... »

FDA approves record 41 new drugs in 2014, over 40% for rare diseases

Friday, January 16, 2015 02:52 PM

Pharmaceutical innovation had a banner year in 2014, as the FDA approved 41 novel drugs and biologics—the largest number in 18 years and a 52% increase from the 27 approved in 2013.

More... »

Optum Labs adds five collaborators

Thursday, January 15, 2015 01:37 PM

Optum Labs, a Cambridge, Mass.-based collaborative research and innovation center co-founded by Optum and Mayo Clinic, has added five new collaborators committed to improving the quality and value of patient care. These include:

More... »


CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs